30.09.2015 - At Pfizer expect revenue growth

Pharmaceutical giant Pfizer raised its revenue forecast for the year, due to the recent acquisition of Hospira. Thus, the company expects to receive 46,5-47,5 billion against the previous forecast of 45-46 billion. We recall that earlier the company bought smaller rival Hospira for $ 16 billion. Given the company's leading position in the market and the stable growth of financial indicators, we expect upside in the medium term by 25-30% per annum.

RISK WARNING: Trading of complex financial products, such as Stocks, Futures, Foreign Exchange ("Forex"), Contracts for Difference ("CFDs"), Indices, Options, or other financial derivatives, on "margin" carries a high level of risk, and may not be suitable for all investors. The possibility exists that you could sustain a loss of some or all of your initial investment and, therefore, you should not invest money that you cannot afford to lose. You should be aware of all the risks associated with trading these markets, and seek advice from an independent financial advisor if you have any questions or doubts. Please carefully read our full "Risk Disclosure" and "Risk Disclosures for Financial Instruments & Investment Services". FXFINPRO Capital is the trading name of PFX Financial Professionals Limited, a limited liability company formed under the laws of Cyprus, registered with the Registrar of Companies in Nicosia, Cyprus, under nr. HE 237840 and regulated by the Cyprus Securities and Exchange Commission with license number 193/13.